We don't have any good treatments for the novel coronavirus right now, but scientists are racing to change that
We don't yet have any drugs designed to fight the novel coronavirus. For now, doctors focus on treating the symptoms of COVID-19, helping keep people alive so their bodies can fight off the virus. Scientists are racing to develop treatments and vaccines to stop the outbreak. Biotech company Gilead is testing a drug call remdesivir, and Moderna has shipped a potential vaccine for initial testing.
Visit Business Insider's homepage for more stories.
As the novel coronavirus spreads around the world, researchers are racing to develop medical treatments to halt it. But for now, hospitals and doctors can only treat the symptoms of COVID-19, helping keep people alive so their bodies can fight off the virus. They're also doing their best to prevent it from spreading to more people. "Usually, just like the flu, it's symptomatic treatment and supportive treatment," Kim Leslie, an emergency-department nursing director at Swedish Hospital in Chicago, told Business Insider. Roughly 80% of coronavirus cases are mild, but 14% are severe — patients have trouble breathing — and 5% are critical, meaning patients are unable to breathe on their own or experience organ failure, according to the Chinese Center for Disease Control and Prevention. Roughly 3% of patients with the virus die.
How doctors treat serious coronavirus cases In the more mild cases, doctors may tell a patient to isolate themselves at home, and to only come to a hospital if the disease gets worse (for instance, if the patient has a hard time breathing). The disease's typical symptoms include a fever, cough, headache, and shortness of breath, according to the US Centers for Disease Control and Prevention. At home, people with the virus should avoid contact with other people and with their pets as much as possible, CDC says. They should also try to avoid passing the virus to others in their household, such as by wearing a mask and washing their hands a lot. Here's what treatment looks like for the most serious cases, according to the CDC and the World Health Organization:
If patients are having trouble breathing, doctors will give them extra oxygen through a face mask or by inserting a breathing tube in more serious cases. In some severe cases, doctors have used a machine that can replace a patients lungs, known as ECMO, or extracorporeal membrane oxygenation. Doctors may give patients antibiotics to fight infections that could come along with COVID-19, the WHO says. But those drugs won't attack the virus itself. In some cases, patients have received drugs designed to fight other viruses, though it's not yet clear which ones work against the new coronavirus. Some patients have gotten drugs usually used against influenza, such as oseltamivir or Tamiflu. Others are getting drugs that fight HIV or viruses similar to the coronavirus.
Both the WHO and CDC also emphasize that medical professionals should take steps to prevent the virus from spreading, such as wearing gloves, masks, and goggles. Scientists are working hard on vaccines and drugs to stop the coronavirus Scientists are racing to develop treatments and vaccines to stop the outbreak. Major drug companies like Gilead are working on this, alongside startups like Moderna. In all, there are more than 100 clinical trials underway testing new and existing drugs, according to a recent article in the Journal of the American Medical Association. The WHO says that remdesivir, a virus-fighting drug from Gilead, is "the most promising candidate." The drug is being tested in multiple trials in people in the US and in Asian countries where the disease is spreading, Gilead has said. The drug company said we'll get the first information on how well remdesivir works in early April. The Trump administration had raised worries that a potential coronavirus treatment might not be affordable, when the administration's top health official said he wouldn't take steps to control its price. But the official, Health and Human Services Secretary Alex Azar, backtracked a day later. "I have directed my teams that if we do any joint venture with a private enterprise, that we're cofunding the research and development program, that we would ensure there's access to the fruits of that, whether vaccine or therapeutics," Azar said. The US government is involved in many of the vaccine and treatment development efforts. The biotech Moderna has created a potential vaccine for the coronavirus that's set to be tested in people starting in April. The first tests will be focused on whether the vaccine is safe, but it'll take months of additional studies to know if it works. There are about 10 other potential vaccines being developed, according to the JAMA article. Experts previously told Business Insider that the coronavirus could become a permanent disease that we have to contend with, just like the flu. That could mean getting a coronavirus vaccine each year, once one is developed, just like the flu shot, New York State Health Commissioner Dr. Howard Zucker said. "As much as this is part of the new normal of diseases, that becomes part of the new normal of response or prevention," Zucker told an audience of public health students and journalists at New York University on Friday. "This has enough of a morbidity, or the potential for mortality, that you would say every season that this is around, you should get this vaccine."
Read more: Everything we know about the coronavirus outbreak A day-by-day breakdown of coronavirus symptoms shows how the disease, COVID-19, goes from bad to worse How the buzzy biotech upstart Moderna sped past Big Pharma to develop the first potential coronavirus vaccine in just 42 days The US is gearing up to test the first coronavirus treatments and vaccines. Here's how 6 top drugmakers are racing to tackle an outbreak that's spreading around the world. Join the conversation about this story » NOW WATCH: Pathologists debunk 13 coronavirus myths
More like this (3)
Gilead plans to spend up to $1 billion to ramp up manufacturing of its coronavirus treatment, but execs dodged Wall Street's questions about turning a profit (GILD)
The California biotech giant Gilead Sciences is planning to spend up to $1 billion to ramp...The California biotech giant Gilead Sciences is planning to spend up to $1 billion to ramp up production of its promising coronavirus treatment remdesivir. The manufacturing ambitions come before the antiviral drug is approved by any health regulators for use in COVID-19, the disease caused by the coronavirus. Hospitalized patients with COVID-19 who got remdesivir recovered 31% faster than a similar group taking placebos, the US National Institutes of Health announced Wednesday. On a Thursday earnings call, Gilead executives said they will donate roughly 1.5 million doses of the drug. But beyond that, they dodged Wall Street's questions about a pricing strategy for the treatment. They pledged to make the drug affordable. Visit Business Insider's homepage for more stories. Gilead Sciences is planning to spend some serious cash to boost production of a promising coronavirus drug. The company is expecting to commit as much as $1 billion to manufacturing the antiviral treatment remdesivir, executives at the biotech company said on a Thursday earnings call. Remdesivir has not been approved to treat coronavirus patients by health regulators. But study results released Wednesday showed the treatment helps patients recover more quickly from COVID-19, the disease caused by the novel coronavirus. The ultimate size of the investment will depend on how the drug's data and the pandemic evolve, said Andrew Dickinson, Gilead's chief financial officer. Through the end of March, Gilead had spent about $50 million on remdesivir, without knowing whether or not it worked. CEO Daniel O'Day said there will be an "exponential increase" in remdesivir supply during the second half of 2020. The biotech anticipates making more than 1 million treatment courses by year's end. Read more: Here's how 13 top drugmakers are sprinting to develop a coronavirus vaccine or treatment that can halt this pandemic The company also pledged to donate its current supply of remdesivir, which amounts to about 140,000 courses of treatment. Looking beyond the immediate term, Gilead executives declined to say how they'll set a price for the pill, which is now the frontrunner to be the first effective coronavirus treatment. Hospitalized patients who got remdesivir recovered 31% faster than a group taking placebo, the US National Institutes of Health found in a clinical trial. The Gilead executives called it "too premature" to discuss pricing for the drug, which is given as an IV infusion in hospitals. Several Wall Street analysts inquired, but company leaders offered little beyond a general aim to make the drug "accessible and affordable." SVB Leerink biotech analyst Geoff Porges, for instance, referenced the profit margins Gilead has made selling medicines for other infectious diseases like HIV and Hepatitis C. "What's special about COVID?" Porges asked. "I don't think there is a precedent for this," O'Day replied, saying a market for a COVID-19 treatment will be unique and different from these other diseases. "There is no rule book out there. other than that we need to be very thoughtful about how we can make sure we provide access of our medicine to patients around the globe and do that in a sustainable way for the company, for you as shareholders, and we acknowledge that," he added. Read more: Coronavirus researchers are crafting drug cocktails with Gilead's antiviral remdesivir, tapping the HIV playbook to fight the coronavirus Later on the call, O'Day said that as the company measures production for remdesivir in the millions of doses, "we have to have a sustainable economic model that works." As the frontrunner in the sprint to an effective COVID-19 treatment, Gilead will be first to face the task of mapping a commercial strategy for a coronavirus drug. At least for now, the company isn't ready to share a plan.Join the conversation about this story » NOW WATCH: 4 potential coronavirus treatments that researchers are working on right now
In a clinical trial, the drug remdesivir shortened recovery time for patients with advanced cases of...In a clinical trial, the drug remdesivir shortened recovery time for patients with advanced cases of COVID-19, the disease caused by the coronavirus.
Just three months after the start of the coronavirus pandemic, several biotech companies are beginning trials...Just three months after the start of the coronavirus pandemic, several biotech companies are beginning trials of promising vaccines and treatments.